Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1 study of ZW251 in advanced solid tumors including hepatocellular carcinoma
jRCT2031250419Phase 1Recruiting
- Sponsor
- Zymeworks Inc.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of ZW251 in hepatocellular carcinoma (HCC) and Nonhematologic neoplasms (2 arms), sponsored by Zymeworks Inc. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) in Part 1, Incidence of adverse events (AEs) in Parts 1 and 2 and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
ZW251
03
Conditions
hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250419.